Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Avanza; Azamianserin; ME-2040; Mepirzapin; Norset; ORG-3770; Promyrtil; Reflex; REFLEX Org3770; Remergil; Remergon; Remeron; RemeronSolTab; Rexer; Zispin

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Organon
  • Developer Meiji Seika Pharma; Merck & Co
  • Class Dibenzazepines; Tetracyclic antidepressants
  • Mechanism of Action Alpha 2 adrenergic receptor antagonists; Serotonin 2 receptor antagonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder
  • Phase II Fibromyalgia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Oct 2015 Phase-II development is ongoing for Fibromyalgia in Japan (PO) (Meiji Seika Pharma pipeline, October 2015)
  • 31 Oct 2014 Meiji Seika Pharma completes a phase II trial in Fibromyalgia in Japan (JapicCTI-122005)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top